Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with a high rate of mortality in patients with ESKD, and vaccination is hoped to prevent infection. Between January 18 and February 24, 2021, 225 kidney transplant recipients (KTRs) and 45 patients on hemodialysis (HDPs) rece...
Gespeichert in:
| Veröffentlicht in: | Journal of the American Society of Nephrology 2021-09, Vol.32 (9), p.2147-2152 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2152 |
|---|---|
| container_issue | 9 |
| container_start_page | 2147 |
| container_title | Journal of the American Society of Nephrology |
| container_volume | 32 |
| creator | Bertrand, Dominique Hamzaoui, Mouad Lemée, Veronique Lamulle, Julie Hanoy, Mélanie Laurent, Charlotte Lebourg, Ludivine Etienne, Isabelle Lemoine, Mathilde Le Roy, Frank Nezam, Dorian Plantier, Jean-Christophe Boyer, Olivier Guerrot, Dominique Candon, Sophie |
| description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with a high rate of mortality in patients with ESKD, and vaccination is hoped to prevent infection.
Between January 18 and February 24, 2021, 225 kidney transplant recipients (KTRs) and 45 patients on hemodialysis (HDPs) received two injections of mRNA BNT162b2 vaccine. The postvaccinal humoral and cellular response was explored in the first 45 KTRs and ten HDPs.
After the second dose, eight HDPs (88.9%) and eight KTRs (17.8%) developed antispike SARS-CoV-2 antibodies ( |
| doi_str_mv | 10.1681/ASN.2021040480 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8729845</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2540513648</sourcerecordid><originalsourceid>FETCH-LOGICAL-c435t-2a27ffbb2444f1612b23d19c0a3e287f691790d0e9a5d014c96851e4179b14833</originalsourceid><addsrcrecordid>eNpVkU1v1DAQhi0Eou3ClSPykUsWj7-SXJDCCiiiLGh36dVynEkxytppnEXac_84pi0FTjOaj_cZzUvIC2BL0BW8brbrJWccmGSyYo_IKSghCiEVe5xzJnWhdSlOyFlKPxgDxcvyKTkREoCXTJ-SmybMvo3dkdrQ0R1d4TDQDaYxhoR0jnTbbLbFKl4WnH7GlDBc4UQ364a-Xe9A85bTS-ucD0h9oJ98F_BId5MNaRxsmLOU86PHMKdbwDnuY-ftcEw-0a92vu08I096OyR8fh8X5Nv7d7vVeXHx5cPHVXNROCnUXHDLy75vWy6l7EFDZosOasesQF6Vva6hrFnHsLaqYyBdrSsFKHO1BVkJsSBv7nTHQ7vHzmX2ZAczTn5vp6OJ1pv_O8F_N1fxp6lKXldSZYFX9wJTvD5gms3eJ5c_ZgPGQzJcSaZA6AxbkOXdqJtiShP2Dxhg5rdzJjtn_jqXF17-e9zD-B-rxC8ZDJLL</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2540513648</pqid></control><display><type>article</type><title>Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Bertrand, Dominique ; Hamzaoui, Mouad ; Lemée, Veronique ; Lamulle, Julie ; Hanoy, Mélanie ; Laurent, Charlotte ; Lebourg, Ludivine ; Etienne, Isabelle ; Lemoine, Mathilde ; Le Roy, Frank ; Nezam, Dorian ; Plantier, Jean-Christophe ; Boyer, Olivier ; Guerrot, Dominique ; Candon, Sophie</creator><creatorcontrib>Bertrand, Dominique ; Hamzaoui, Mouad ; Lemée, Veronique ; Lamulle, Julie ; Hanoy, Mélanie ; Laurent, Charlotte ; Lebourg, Ludivine ; Etienne, Isabelle ; Lemoine, Mathilde ; Le Roy, Frank ; Nezam, Dorian ; Plantier, Jean-Christophe ; Boyer, Olivier ; Guerrot, Dominique ; Candon, Sophie</creatorcontrib><description>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with a high rate of mortality in patients with ESKD, and vaccination is hoped to prevent infection.
Between January 18 and February 24, 2021, 225 kidney transplant recipients (KTRs) and 45 patients on hemodialysis (HDPs) received two injections of mRNA BNT162b2 vaccine. The postvaccinal humoral and cellular response was explored in the first 45 KTRs and ten HDPs.
After the second dose, eight HDPs (88.9%) and eight KTRs (17.8%) developed antispike SARS-CoV-2 antibodies (
<0.001). Median titers of antibodies in responders were 1052 AU/ml (IQR, 515-2689) in HDPs and 671 AU/ml (IQR, 172-1523) in KTRs (
=0.40). Nine HDPs (100%) and 26 KTRs (57.8%) showed a specific T cell response (
=0.06) after the second injection. In responders, median numbers of spike-reactive T cells were 305 SFCs per 10
CD3+ T cells (IQR, 95-947) in HDPs and 212 SFCs per 10
CD3+ T cells (IQR, 61-330) in KTRs (
=0.40). In KTRs, the immune response to BNT162b2 seemed influenced by the immunosuppressive regimen, particularly tacrolimus or belatacept.
Immunization with BNT162b2 seems more efficient in HDPs, indicating that vaccination should be highly recommended in these patients awaiting a transplant. However, the current vaccinal strategy for KTRs may not provide effective protection against COVID-19 and will likely need to be improved.</description><identifier>ISSN: 1046-6673</identifier><identifier>ISSN: 1533-3450</identifier><identifier>EISSN: 1533-3450</identifier><identifier>DOI: 10.1681/ASN.2021040480</identifier><identifier>PMID: 34112706</identifier><language>eng</language><publisher>United States: American Society of Nephrology</publisher><subject>Aged ; Antibodies, Viral - biosynthesis ; BNT162 Vaccine ; Cohort Studies ; COVID-19 - complications ; COVID-19 - immunology ; COVID-19 - prevention & control ; COVID-19 Vaccines - administration & dosage ; COVID-19 Vaccines - pharmacology ; Female ; Humans ; Immunocompromised Host ; Immunosuppressive Agents - adverse effects ; Kidney Failure, Chronic - complications ; Kidney Failure, Chronic - immunology ; Kidney Failure, Chronic - therapy ; Kidney Transplantation - adverse effects ; Male ; Middle Aged ; Pandemics ; Rapid Communications ; Renal Dialysis ; Retrospective Studies ; RNA, Messenger - genetics ; SARS-CoV-2 - genetics ; SARS-CoV-2 - immunology ; Spike Glycoprotein, Coronavirus - genetics ; Spike Glycoprotein, Coronavirus - immunology ; T-Lymphocytes - immunology ; Transplant Recipients</subject><ispartof>Journal of the American Society of Nephrology, 2021-09, Vol.32 (9), p.2147-2152</ispartof><rights>Copyright © 2021 by the American Society of Nephrology.</rights><rights>Copyright © 2021 by the American Society of Nephrology 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c435t-2a27ffbb2444f1612b23d19c0a3e287f691790d0e9a5d014c96851e4179b14833</citedby><cites>FETCH-LOGICAL-c435t-2a27ffbb2444f1612b23d19c0a3e287f691790d0e9a5d014c96851e4179b14833</cites><orcidid>0000-0002-5953-5785 ; 0000-0002-7591-307 ; 0000-0002-7591-307X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729845/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729845/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,725,778,782,883,27907,27908,53774,53776</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34112706$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bertrand, Dominique</creatorcontrib><creatorcontrib>Hamzaoui, Mouad</creatorcontrib><creatorcontrib>Lemée, Veronique</creatorcontrib><creatorcontrib>Lamulle, Julie</creatorcontrib><creatorcontrib>Hanoy, Mélanie</creatorcontrib><creatorcontrib>Laurent, Charlotte</creatorcontrib><creatorcontrib>Lebourg, Ludivine</creatorcontrib><creatorcontrib>Etienne, Isabelle</creatorcontrib><creatorcontrib>Lemoine, Mathilde</creatorcontrib><creatorcontrib>Le Roy, Frank</creatorcontrib><creatorcontrib>Nezam, Dorian</creatorcontrib><creatorcontrib>Plantier, Jean-Christophe</creatorcontrib><creatorcontrib>Boyer, Olivier</creatorcontrib><creatorcontrib>Guerrot, Dominique</creatorcontrib><creatorcontrib>Candon, Sophie</creatorcontrib><title>Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients</title><title>Journal of the American Society of Nephrology</title><addtitle>J Am Soc Nephrol</addtitle><description>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with a high rate of mortality in patients with ESKD, and vaccination is hoped to prevent infection.
Between January 18 and February 24, 2021, 225 kidney transplant recipients (KTRs) and 45 patients on hemodialysis (HDPs) received two injections of mRNA BNT162b2 vaccine. The postvaccinal humoral and cellular response was explored in the first 45 KTRs and ten HDPs.
After the second dose, eight HDPs (88.9%) and eight KTRs (17.8%) developed antispike SARS-CoV-2 antibodies (
<0.001). Median titers of antibodies in responders were 1052 AU/ml (IQR, 515-2689) in HDPs and 671 AU/ml (IQR, 172-1523) in KTRs (
=0.40). Nine HDPs (100%) and 26 KTRs (57.8%) showed a specific T cell response (
=0.06) after the second injection. In responders, median numbers of spike-reactive T cells were 305 SFCs per 10
CD3+ T cells (IQR, 95-947) in HDPs and 212 SFCs per 10
CD3+ T cells (IQR, 61-330) in KTRs (
=0.40). In KTRs, the immune response to BNT162b2 seemed influenced by the immunosuppressive regimen, particularly tacrolimus or belatacept.
Immunization with BNT162b2 seems more efficient in HDPs, indicating that vaccination should be highly recommended in these patients awaiting a transplant. However, the current vaccinal strategy for KTRs may not provide effective protection against COVID-19 and will likely need to be improved.</description><subject>Aged</subject><subject>Antibodies, Viral - biosynthesis</subject><subject>BNT162 Vaccine</subject><subject>Cohort Studies</subject><subject>COVID-19 - complications</subject><subject>COVID-19 - immunology</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Vaccines - administration & dosage</subject><subject>COVID-19 Vaccines - pharmacology</subject><subject>Female</subject><subject>Humans</subject><subject>Immunocompromised Host</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Kidney Failure, Chronic - complications</subject><subject>Kidney Failure, Chronic - immunology</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Kidney Transplantation - adverse effects</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pandemics</subject><subject>Rapid Communications</subject><subject>Renal Dialysis</subject><subject>Retrospective Studies</subject><subject>RNA, Messenger - genetics</subject><subject>SARS-CoV-2 - genetics</subject><subject>SARS-CoV-2 - immunology</subject><subject>Spike Glycoprotein, Coronavirus - genetics</subject><subject>Spike Glycoprotein, Coronavirus - immunology</subject><subject>T-Lymphocytes - immunology</subject><subject>Transplant Recipients</subject><issn>1046-6673</issn><issn>1533-3450</issn><issn>1533-3450</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkU1v1DAQhi0Eou3ClSPykUsWj7-SXJDCCiiiLGh36dVynEkxytppnEXac_84pi0FTjOaj_cZzUvIC2BL0BW8brbrJWccmGSyYo_IKSghCiEVe5xzJnWhdSlOyFlKPxgDxcvyKTkREoCXTJ-SmybMvo3dkdrQ0R1d4TDQDaYxhoR0jnTbbLbFKl4WnH7GlDBc4UQ364a-Xe9A85bTS-ucD0h9oJ98F_BId5MNaRxsmLOU86PHMKdbwDnuY-ftcEw-0a92vu08I096OyR8fh8X5Nv7d7vVeXHx5cPHVXNROCnUXHDLy75vWy6l7EFDZosOasesQF6Vva6hrFnHsLaqYyBdrSsFKHO1BVkJsSBv7nTHQ7vHzmX2ZAczTn5vp6OJ1pv_O8F_N1fxp6lKXldSZYFX9wJTvD5gms3eJ5c_ZgPGQzJcSaZA6AxbkOXdqJtiShP2Dxhg5rdzJjtn_jqXF17-e9zD-B-rxC8ZDJLL</recordid><startdate>202109</startdate><enddate>202109</enddate><creator>Bertrand, Dominique</creator><creator>Hamzaoui, Mouad</creator><creator>Lemée, Veronique</creator><creator>Lamulle, Julie</creator><creator>Hanoy, Mélanie</creator><creator>Laurent, Charlotte</creator><creator>Lebourg, Ludivine</creator><creator>Etienne, Isabelle</creator><creator>Lemoine, Mathilde</creator><creator>Le Roy, Frank</creator><creator>Nezam, Dorian</creator><creator>Plantier, Jean-Christophe</creator><creator>Boyer, Olivier</creator><creator>Guerrot, Dominique</creator><creator>Candon, Sophie</creator><general>American Society of Nephrology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5953-5785</orcidid><orcidid>https://orcid.org/0000-0002-7591-307</orcidid><orcidid>https://orcid.org/0000-0002-7591-307X</orcidid></search><sort><creationdate>202109</creationdate><title>Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients</title><author>Bertrand, Dominique ; Hamzaoui, Mouad ; Lemée, Veronique ; Lamulle, Julie ; Hanoy, Mélanie ; Laurent, Charlotte ; Lebourg, Ludivine ; Etienne, Isabelle ; Lemoine, Mathilde ; Le Roy, Frank ; Nezam, Dorian ; Plantier, Jean-Christophe ; Boyer, Olivier ; Guerrot, Dominique ; Candon, Sophie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c435t-2a27ffbb2444f1612b23d19c0a3e287f691790d0e9a5d014c96851e4179b14833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Antibodies, Viral - biosynthesis</topic><topic>BNT162 Vaccine</topic><topic>Cohort Studies</topic><topic>COVID-19 - complications</topic><topic>COVID-19 - immunology</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Vaccines - administration & dosage</topic><topic>COVID-19 Vaccines - pharmacology</topic><topic>Female</topic><topic>Humans</topic><topic>Immunocompromised Host</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Kidney Failure, Chronic - complications</topic><topic>Kidney Failure, Chronic - immunology</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Kidney Transplantation - adverse effects</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pandemics</topic><topic>Rapid Communications</topic><topic>Renal Dialysis</topic><topic>Retrospective Studies</topic><topic>RNA, Messenger - genetics</topic><topic>SARS-CoV-2 - genetics</topic><topic>SARS-CoV-2 - immunology</topic><topic>Spike Glycoprotein, Coronavirus - genetics</topic><topic>Spike Glycoprotein, Coronavirus - immunology</topic><topic>T-Lymphocytes - immunology</topic><topic>Transplant Recipients</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bertrand, Dominique</creatorcontrib><creatorcontrib>Hamzaoui, Mouad</creatorcontrib><creatorcontrib>Lemée, Veronique</creatorcontrib><creatorcontrib>Lamulle, Julie</creatorcontrib><creatorcontrib>Hanoy, Mélanie</creatorcontrib><creatorcontrib>Laurent, Charlotte</creatorcontrib><creatorcontrib>Lebourg, Ludivine</creatorcontrib><creatorcontrib>Etienne, Isabelle</creatorcontrib><creatorcontrib>Lemoine, Mathilde</creatorcontrib><creatorcontrib>Le Roy, Frank</creatorcontrib><creatorcontrib>Nezam, Dorian</creatorcontrib><creatorcontrib>Plantier, Jean-Christophe</creatorcontrib><creatorcontrib>Boyer, Olivier</creatorcontrib><creatorcontrib>Guerrot, Dominique</creatorcontrib><creatorcontrib>Candon, Sophie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of the American Society of Nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bertrand, Dominique</au><au>Hamzaoui, Mouad</au><au>Lemée, Veronique</au><au>Lamulle, Julie</au><au>Hanoy, Mélanie</au><au>Laurent, Charlotte</au><au>Lebourg, Ludivine</au><au>Etienne, Isabelle</au><au>Lemoine, Mathilde</au><au>Le Roy, Frank</au><au>Nezam, Dorian</au><au>Plantier, Jean-Christophe</au><au>Boyer, Olivier</au><au>Guerrot, Dominique</au><au>Candon, Sophie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients</atitle><jtitle>Journal of the American Society of Nephrology</jtitle><addtitle>J Am Soc Nephrol</addtitle><date>2021-09</date><risdate>2021</risdate><volume>32</volume><issue>9</issue><spage>2147</spage><epage>2152</epage><pages>2147-2152</pages><issn>1046-6673</issn><issn>1533-3450</issn><eissn>1533-3450</eissn><abstract>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with a high rate of mortality in patients with ESKD, and vaccination is hoped to prevent infection.
Between January 18 and February 24, 2021, 225 kidney transplant recipients (KTRs) and 45 patients on hemodialysis (HDPs) received two injections of mRNA BNT162b2 vaccine. The postvaccinal humoral and cellular response was explored in the first 45 KTRs and ten HDPs.
After the second dose, eight HDPs (88.9%) and eight KTRs (17.8%) developed antispike SARS-CoV-2 antibodies (
<0.001). Median titers of antibodies in responders were 1052 AU/ml (IQR, 515-2689) in HDPs and 671 AU/ml (IQR, 172-1523) in KTRs (
=0.40). Nine HDPs (100%) and 26 KTRs (57.8%) showed a specific T cell response (
=0.06) after the second injection. In responders, median numbers of spike-reactive T cells were 305 SFCs per 10
CD3+ T cells (IQR, 95-947) in HDPs and 212 SFCs per 10
CD3+ T cells (IQR, 61-330) in KTRs (
=0.40). In KTRs, the immune response to BNT162b2 seemed influenced by the immunosuppressive regimen, particularly tacrolimus or belatacept.
Immunization with BNT162b2 seems more efficient in HDPs, indicating that vaccination should be highly recommended in these patients awaiting a transplant. However, the current vaccinal strategy for KTRs may not provide effective protection against COVID-19 and will likely need to be improved.</abstract><cop>United States</cop><pub>American Society of Nephrology</pub><pmid>34112706</pmid><doi>10.1681/ASN.2021040480</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-5953-5785</orcidid><orcidid>https://orcid.org/0000-0002-7591-307</orcidid><orcidid>https://orcid.org/0000-0002-7591-307X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1046-6673 |
| ispartof | Journal of the American Society of Nephrology, 2021-09, Vol.32 (9), p.2147-2152 |
| issn | 1046-6673 1533-3450 1533-3450 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8729845 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Aged Antibodies, Viral - biosynthesis BNT162 Vaccine Cohort Studies COVID-19 - complications COVID-19 - immunology COVID-19 - prevention & control COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - pharmacology Female Humans Immunocompromised Host Immunosuppressive Agents - adverse effects Kidney Failure, Chronic - complications Kidney Failure, Chronic - immunology Kidney Failure, Chronic - therapy Kidney Transplantation - adverse effects Male Middle Aged Pandemics Rapid Communications Renal Dialysis Retrospective Studies RNA, Messenger - genetics SARS-CoV-2 - genetics SARS-CoV-2 - immunology Spike Glycoprotein, Coronavirus - genetics Spike Glycoprotein, Coronavirus - immunology T-Lymphocytes - immunology Transplant Recipients |
| title | Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T07%3A16%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibody%20and%20T%20Cell%20Response%20to%20SARS-CoV-2%20Messenger%20RNA%20BNT162b2%20Vaccine%20in%20Kidney%20Transplant%20Recipients%20and%20Hemodialysis%20Patients&rft.jtitle=Journal%20of%20the%20American%20Society%20of%20Nephrology&rft.au=Bertrand,%20Dominique&rft.date=2021-09&rft.volume=32&rft.issue=9&rft.spage=2147&rft.epage=2152&rft.pages=2147-2152&rft.issn=1046-6673&rft.eissn=1533-3450&rft_id=info:doi/10.1681/ASN.2021040480&rft_dat=%3Cproquest_pubme%3E2540513648%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2540513648&rft_id=info:pmid/34112706&rfr_iscdi=true |